Posted on

Innovation is the Key Benchmark, Focus on Four Healthcare Industry Sub-Sectors in 2023, Says Jafar Wang of Legend Capital

HONG KONG, Feb 15, 2023 - (ACN Newswire via SEAPRWire.com) - Legend Capital invested in 29 healthcare companies that officially disclosed financing rounds in 2022, according to the VBDATA Database. Since 2007, Legend Capital has continuously invested in healthcare across industry sub-sectors including innovative drugs, biotechnology, medical devices, diagnostic technology, professional services and supply chain. Overtime, it has built a powerful healthcare ecosystem encompassing more than 140 portfolio companies. Through value-added initiatives including strategic management and business empowerment activities, Legend Capital has the capability to bring far more value to the table in addition to financial resources.Breakthrough and global innovations are the key benchmarks by which Legend Capital judges and selects projects in a changing external environment. How did Legend Capital navigate the challenges of 2022 and how does it see the market in 2023? What are the key healthcare investment themes? In an interview with VCBeat, Jafar Wang, Co-Chief Investment Officer of Legend Capital, shared his perspectives:"Five significant changes in primary market investments"Legend Capital observed several important evolvements in the healthcare investment market during 2022:First, the industry's overall investment pace slowed down, with considerable decrease in deal count, deal size, and the speed of decision-making. Activity level of the healthcare investment market has returned to normalcy after an overheated period of 2020-2021, which now appears on the same level as 2019. Second, there has been significant changes in investors' selection criteria. Institutional investors need to evaluate whether a project has demonstrated breakthrough innovation, whether it is among the top three in its field, and whether it has the potential to compete on the global stage for first-in-class or best-in-class status. As a result, investors look to sector leaders for investment opportunities.Third, there is growing emphasis on exit and exit management.Fourth, emerging markets are receiving more attention as industry participants turn their overseas focus from developed markets to emerging economies. On the one hand, investors have increased their allocation to emerging markets, such as Legend Capital's expansion into Southeast Asia. Similarly, more players are aggressively expanding abroad in the hope that their products and services will reach the wider emerging markets. For Chinese healthcare companies, these markets will be a key destination in the next five to ten years.Lastly, there is general awareness in the industry that the window for biotech companies to transition into biopharma has closed for the moment. Biotech companies should continue to focus on their core competencies in technology innovation and product development, while actively pursue collaborations in manufacturing, supply chain, and downstream commercialization with top-tier industry players."An investment strategy focused on innovation and early-stage opportunities" Regardless of changes to the external environment, Legend Capital continues to uphold the importance of being an investor in value, innovation, in early-stage firms, in core technologies, and taking the long view. Our selection criteria for deals remain consistently high.In 2022, Legend Capital established a Frontier Biotechnology Fund to invest in innovative seed and start-up stage biotechnology and MedTech companies. Although such investments carry higher risks, they could potentially create game-changing results for the industry. This fund will mainly focus on the commercialization of ideas and products from academia, overseas returnees, and well-known spin-off teams or founders. Legend Capital values cutting-edge, innovative, and disruptive technologies, and we are willing to make bigger bets and dedicate more resources towards these seed and angel stage projects.Legend Capital is also devoted to investing in the independence and security of the healthcare supply chain. Two years ago, we put forward the view that an independent and secure supply chain, as well as import substitution, are among the best investment opportunities over the next five years. We are not only focused on the China market, but with an eye to the international potential of investee companies. The idea of supply chain investment is to help resolve bottlenecks faced by the industry while also serving the global market.In terms of Legend Capital's healthcare ecosystem, we are continuously expanding this ecosystem and improving synergies within. In the past, our value-added services were geared towards management guidance, but two years ago, we increased efforts to empower our portfolio companies with industry perspectives. To date, Legend Capital has invested in more than 140 healthcare companies, and established a complete, one-stop value-added service system across research, production, supply chain, and commercialization function. Our presence in sub-sectors from life science tools to preclinical research, clinical CRO, manufacturing and commercialization allow Legend Capital to bring synergy to portfolio companies. As this value-add ecosystem evolve and portfolio companies reap the benefits, oftentimes prospective investees become more receptive to our investment; they see Legend Capital as an investor with abundant industry resources, rather than a pure financial investor.Additionally, Legend Capital cooperates closely with industry-leading firms to bring additional resources to our healthcare ecosystem, which helps portfolio companies in their business development. Through product licensing and strategic collaborations, we have strengthened the connection among the ecosystem, portfolio companies, and industry peers. Working with healthcare companies in the industry not only aids the development of our portfolio companies, but also present potential new opportunities for Legend Capital. For instance, we have been able to generate new investments with our industry partners through efforts such as co-investments, incubation, and spin-offs. This may very well become a common investment practice in the future.Throughout 2022, Legend Capital had five healthcare-related IPOs, including Recbio Technology, R&G Pharmastudies, MicuRx Pharmaceutical, Sipai Health Technology, and Lunit; in addition, nearly 10 portfolio companies were exited through M&A. A RMB 300+ million GP-led secondary transaction was completed during the year after concluding a $270 million one in 2021. We will continue to utilize secondary tools in the future to generate large-scale exits for existing LPs, which also create opportunities to partner with new LPs while supporting our portfolio companies on their journeys, to ultimately achieve a win-win for all parties."Opportunities are bred from innovation" Legend Capital maintains a diversified portfolio of companies in innovative drugs and biotechnology, medical devices and diagnostic technology, professional service and supply chain, and will continue to actively invest going forward. In 2023, our healthcare investment efforts will focus on three main areas.For biotech, Legend Capital will concentrate on small nucleic acid medicines and CGT-related verticals such as gene editing and induced pluripotent stem cells. In MedTech, more focus will be placed on life science tools, import substitution, and consumer healthcare. In professional services and supply chain, with the evolvement of CGT and small nucleic acid pharmaceuticals, CRO and CDMO may present new investment prospects. In addition to investing in pharmaceutical CRO and CDMO, Legend Capital saw success in 2022 with investments in medical device and diagnostic CRO and CDMO so we will continue to invest in these fields.Leveraging our vast portfolio ecosystem, Legend Capital will continue to make significant investments in supply chain independence, including upstream consumables, machinery, and life science tools. To achieve the best outcomes, Legend Capital will collaborate with its leading portfolio companies in the future on co-investments and help them with potential M&A opportunities.In summary, Legend Capital believes that the best investment opportunities arise from breakthrough innovation. For instance, our portfolio company Harbour BioMed recently announced that the U.S. FDA has cleared the IND application to commence clinical trials of its globally first-in-class fully human monoclonal antibody HBM1020 targeting B7H7 (also known as HHLA2) in the U.S. HBM1020 is also the globally first-ever monoclonal antibody targeting B7H7 cleared by the regulatory agency for clinical trials. HBM1020 may present a novel anti-tumor therapeutic complementary to PD-(L)1 therapeutics to patients, especially for PD-L1 negative/refractory patients. Regardless of the outcome, we believe a company will stand a better chance to break out from intense competition when it has the courage and boldness to be the innovator.About Legend CapitalFounded in 2001, Legend Capital is a leading VC&PE investor focusing on the early-stage and growth-stage opportunities in China, with offices across Beijing, Shanghai, Shenzhen, Hong Kong, and Seoul, Korea. It currently manages USD and RMB funds of over US$10 billion in commitments, and has invested in around 600 companies, covering technology, healthcare, consumer, enterprise service and intelligent manufacturing sectors. Rooted in China, Legend Capital participated in the rise of many world-leading companies by solid investment coverage and systematic post-investment value-add. Over the years, Legend Capital has also become a widely recognized name in bridging key resources in China and overseas through cross-border activities, and a valuable partner to Chinese and overseas investors. Legend Capital values long-term sustainable investment and incorporates ESG into its long-term development strategy. As a UNPRI signatory since November 2019, Legend Capital is among the first group of top VC/PE firms in China to join the initiative. For more information, please visit www.legendcapital.com.cn/index_en.aspx and follow us on LinkedIn @Legend Capital (https://www.linkedin.com/company/legend-capital). Copyright 2023 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

Sunway RE Capital Expands Student Accommodation Portfolio with New Acquisition of Freehold Purpose-Built Student Accommodation, Green Wood Court, in Southampton, UK

With 233 beds arranged as 217 non en-suites and 16 studios, Green Wood Court has achieved a 100% occupancy rate for the academic year 2022/2023The freehold Purpose-Built Student Accommodation ("PBSA"), Green Wood Court, is located just a few minutes' walk from the University of Southampton's Highfield and Bolderwood campuses with established connection links to the UK and rest of EuropeGreen Wood Court has undergone extensive refurbishments in 2018 and there are opportunities for asset enhancement initiatives to add new studios within the PBSAUniversity of Southampton is a global top 100 university and is also ranked one of the top 13 university in the UK, with a community of over 6,500 international students from 135 countriesResilient, healthy demand for Green Wood Court by students of University of Southamptonwith limited supply of PBSAs in the areaPost-acquisition, Sunway RE Capital owns and manages a portfolio of 5 PBSA assets (AUM of £75 million) with over 800 beds spanning across key cities in the UKMalaysia, Singapore, Feb 6, 2023 - (ACN Newswire via SEAPRWire.com) - Sunway RE Capital ("Sunway RE Capital"), a platform for international real estate investments of Sunway Group - one of Southeast Asia's leading conglomerates, is pleased to announce the expansion of its student accommodation portfolio with the acquisition of a new freehold PBSA, Green Wood Court, in Southampton, UK, through its established and sponsored private trust established in Singapore, Sunway Residence Trust II.Strategically located with a few minutes' walk from the University of Southampton's Highfield and Bolderwood campuses, the 233-bed freehold PBSA, Green Wood Court, also has a bus stop situated directly in front of the property that facilitates ease of access to the rest of the University's halls and campuses, as well as established connection links to the UK and rest of Europe.Green Wood Court has achieved a 100% occupancy rate for the academic year 2022/2023 and in 2018, Green Wood Court has been extensively refurbished with new carpets, bathrooms, showers, furniture, and fittings in 2018. Please see APPENDIX A of this press release for pictures of Green Wood Court.There are opportunities for asset enhancement initiatives to add new studios within Green Wood Court and following the acquisition, Sunway RE Capital will be exploring its options to optimise the potential of this PBSA.According to Universities and Colleges Admissions Service, universities in the UK are seeking to stabilise student numbers after a surge over the last two years amid the COVID pandemic. The trend is likely to continue in the coming years, as universities in the UK grapple with growing numbers of applications due to an increase in the number of 18-year-olds in the UK population. This is projected to continue for a decade, rising 2-3% almost every year with international student numbers growing as well.Ranked as the 6th safest big city in the UK, the University of Southampton's campuses are located in prosperous and green areas of Southampton. A global top 100 university, the University of Southampton is also ranked as one of the top 13 university in the UK with a community of over 6,500 international students from 135 different countries.Post-acquisition, Sunway RE Capital owns and manages a portfolio of 5 PBSA assets (AUM of £75 million) with over 800 beds spanning across key cities in the UK.Sunway RE Capital Chief Executive Officer, Dr. Tan Kok Heng, said: "The demand for quality education overseas continues to see a steady rise post pandemic and the UK remains one of the most popular destination for overseas students in the world. With its 100% occupancy rate and limited supply of PBSAs in the area, the acquisition of the 233-bed Green Wood Court in Southampton, UK, marks an attractive addition to our PBSA portfolio and it is consistent with our fund strategy to achieve steady and stable income streams, with potential value-added upside through active asset management and enhancement initiatives.Building on this momentum and the strength of Sunway's track record and competencies, we aim to accelerate our efforts to scale up our platform to acquire additional yield accretive student accommodations in the UK, grow our AUM and extend our track record."For more information on Sunway RE Capital, please visit: www.sunwayrecapital.comAbout Sunway GroupEstablished in 1974, Sunway Group is one of Southeast Asia's leading conglomerates with 13 business divisions across more than 50 locations primarily in Asia. Our 16,000-strong team is committed to sustainable development and socio-economic progress through our diverse businesses including core interests in real estate, construction, education, healthcare, retail and hospitality.Sunway is committed to advancing the United Nations Sustainable Development Goals and continues to align them with our Environmental, Social and Governance (ESG) targets as part of our corporate strategy and social responsibility towards driving the group's long-term success and deepening our commitment to nation-building.Our three public-listed companies — Sunway Berhad, Sunway Construction Group Berhad, and Sunway REIT, with a combined market capitalisation of RM 15 billion — form a real-estate value chain that exemplifies socially responsible business practices. For more information, visit www.sunway.com.my.About Sunway RE Capital Pte LtdSunway RE Capital Pte Ltd invests in listed and unlisted funds established in Singapore. Sunway RE Capital's objective is to invest in real estate for recurring income along with a fund management platform. Its key investment focus is commercial properties and purpose-built student accommodation (PBSA) primarily in the United Kingdom. For more information, visit www.sunwayrecapital.comSunway RE Capital is also one of the sponsors of Elite Commercial REIT (ECR) which is listed in Singapore since February 2020 with a market capitalisation of £227 million. ECR is the first and only UK- Focused S-REIT which comprises 155 predominantly freehold quality commercial buildings ("Portfolio") located across the UK with an aggregate value of £517.7 million. The Portfolio has a total net internal area of approximately 3.9 million square feet and a total site area of approximately 72 hectares. For more information, visit www.elitecreit.com.About Sunway Residence Trust IISunway Residence Trust II, sponsored by Sunway RE Capital Pte Ltd, is a private trust established in Singapore that aims to create a stable recurring income with potential growth in net asset value to its investors. This fund approaches its acquisition strategy by a two-level approach namely geographical allocation and diversification of the portfolio as well as micro location of the assets.With the primary goal being acquisition of assets within the Russell Group Universities cities, the trust carefully examines potential assets and their occupancy demand prior to their acquisition decision. Standing with a current portfolio of £75 million valuation, 828 beds, and less than 5 years of average asset age, Sunway Residence Trust II currently owns assets such as Green Wood Court, Redvers Tower, The Colston, Centre Gate, and Mansion Point. For more information, visit https://sunwayrecapital.com/portfolio/sunway-residence-trust/.Issued on behalf of Sunway RE Capital by 8PR Asia Pte Ltd.Media Contact: Mr. Alex TANMobile: +65 9451 5252Email: alex.tan@8prasia.com Copyright 2023 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

Broadhill Capital Announces its Capital Deployment Strategy for 2023

LOS ANGELES, CA, Jan 24, 2023 - (ACN Newswire via SEAPRWire.com) - Broadhill Capital announced today that the firm will target to commit equity investment of USD $15 Billion across approximately 100-150 businesses. "We expect to make non-control equity investments into businesses that have the potential to achieve 5-10x revenue growth with our capital commitment," stated investment committee member Francis König. "We separate ourselves by our willingness to assist businesses in situations that often appear high risk to more conservative investors."Investment commitments are expected to range between USD $50 Million to $5 Billion per company, with most falling between USD $100-500 Million. Businesses must either be public or be positioned and agree to become publicly listed on a major global stock exchange within 3 years. Most business types, industries, and geographies are eligible, provided the business activities are legal in the United States, and in the countries where the business operates. Due diligence and transaction approval should typically be completed within 30 days.Businesses seeking equity investment may submit their opportunity for immediate consideration through the BroadhillCapital.com website by using the link: https://broadhillcapital.com/submit-business/.Source: Broadhill Capital LLCMedia Contact: press@broadhillcapital.com Copyright 2023 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

Avendus appoints Sumit Dayal as Independent Non-Executive Director in Singapore

SINGAPORE, Jan 10, 2023 - (ACN Newswire via SEAPRWire.com) - Avendus, one of India's leading institutional financial services companies, announced the appointment of Sumit Dayal as Independent Non-Executive Director in Singapore today. He will provide guidance and corporate governance oversight as a Board member to Avendus Capital Pte. Limited (Singapore).Sumit DayalA seasoned banker with over 30 years of corporate and investment banking experience, spent 16 years as Managing Director and headed various business units of Standard Chartered Bank in Singapore and Hong Kong. He also spent over 13 years in multiple roles in Bank of America across client risk and client coverage based in India, Singapore, and Hong Kong in the past.Commenting on the appointment, Gaurav Deepak, Co-founder and CEO, Avendus Capital said, "We are delighted that Sumit has decided to join Avendus Singapore. We're confident that his exceptional experience and advisory will be of immense value to the franchise as we focus on making Singapore a strong base to grow our institutional franchise in Investment Banking, Institutional Equities and Wealth Management."Sumit Dayal, Independent Non-Executive Director, Avendus Capital Pte. Limited said, "I am delighted to join Avendus. It's an institution that has been built on very strong fundamentals and one that I have admired immensely. I am looking forward to working with the firm to further deepen its linkages in the APAC region."About Avendus Avendus Group is a leading financial services firm with presence in the areas of Investment Banking, Wealth Management, Credit Solutions and Asset Management. Established in 1999 in Mumbai, India, Avendus is today present in 10 cities across India, US, UK and Singapore. Avendus partners with the Indian entrepreneur ecosystem to provide differentiated solutions that enable clients to meet their strategic aspirations.Avendus Capital, the investment banking arm, is consistently ranked among the top investment banks in the country on the back of its in-depth domain understanding and a best in the class track record of domestic and cross-border transactions. Avendus' wide range of clients is testimony to its ability to serve its corporates throughout their life cycle -- from growth stage funding to large-sized transactions and M&A advisory. Avendus Capital Inc located in New York is an Avendus Group entity offering M&A and Private Equity syndication services to clients in the US. Avendus Capital Pte Limited located in Singapore is an Avendus Group entity undertaking Fund Management business in Singapore. For more information, please visit www.avendus.com. Copyright 2023 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

JP Morgan, Citi, BNP Paribas, Barclays, and Lloyds Banking Group make new strategic investment in operational risk management firm Acin

LONDON, Dec 15, 2022 - (ACN Newswire via SEAPRWire.com) - Acin, the global operational risk control data network, today announced it has closed $24 million in Series B funding from a strategic consortium of industry-leading banks, comprised of JP Morgan, Citi, BNP Paribas, Barclays, and Lloyds Banking Group.The funding round was also supported by existing investors Notion Capital, Talis Capital and Fitch Ventures, the equity investment arm of Fitch Group.This funding will enable further strategic product development in partnership with investing banks and existing clients. Additionally, it will enable Acin to expand and accelerate into new areas across the financial services industry.Acin's platform empowers financial institutions to digitise their operational and non-financial risk analysis, using ground breaking data analytic capabilities. Acin has established a network that calibrates data and facilitates the sharing of best practice between firms, underpinned by a standardised library of risks and controls. The results revolutionise the understanding and management of firms' operational and non-financial risk positions accelerating their journey to become safer and more efficient. Minimising operational risk capital is a shared industry ambition and Acin's solution is a key building block.Click on, or paste the following link into your web browser, to view the associated PDF document.http://www.rns-pdf.londonstockexchange.com/rns/7475J_1-2022-12-14.pdf This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

Legend Capital Portfolio Company Bespin Global Completes USD100m Series D Financing

HONG KONG, Dec 15, 2022 - (ACN Newswire via SEAPRWire.com) - Legend Capital Portfolio Company Bespin Global, a Korea-headquartered cloud services company, has recently completed its Series D round financing of USD100 million, which will be used mostly for acquisitions.Concurrent with the investment, the investor, e& Enterprise, a leading digital services provider in UAE (formerly Etisalat Digital), and Bespin Global will form a joint venture that will serve customers in the Middle East, North Africa and Pakistan.John HanJoo Lee, CEO and co-founder of Bespin Global said, "By combining forces with e& enterprise in the METAP region, we are bringing much needed cloud managed services to the region where cloud adoption is about to explode. e& enterprise has deep customer relationships and the trust of its customers and Bespin Global has the deep cloud management capabilities. Together, we can accelerate cloud adoption in the region. Additionally, we welcome e& as our shareholder. It's a clear validation of our track record as a trusted cloud managed services provider on the global stage."Bespin Global helps its customers in their digital transformation by providing cloud migration, cloud management and related SaaS offerings. It is the first multi-cloud managed service provider in East Asia with partnerships with Amazon Web Services, Microsoft Azure, Google Cloud, Aliyun, Tencent Cloud, and Naver Cloud.The company has offices in 9 countries including Korea, China, Japan, Singapore, Vietnam, Indonesia, the US, UAE, and Saudi Arabia. It has over 1,700 customers which range from large enterprises to fast growing startups.Legend Capital led Bespin Global's Series A financing in 2017, and continued to invest in the company's Series B financing in 2019. As an early investor, Legend Capital has provided support and help to Bespin Global in global cooperation, enterprise management and subsequent financing, to promote Bespin Global's development.In 2020, Legend Capital introduced Serverworks, a leading AWS Cloud integrator in Japan, to Bespin Global. The two companies established a joint venture in September 2021, entering the Japanese market officially.John HanJoo Lee, CEO and co-founder of Bespin Global said, "It was Legend Capital that first introduced us to the UAE investors that led to the successful funding round with e&. Many venture capital firms talk about adding value, but only a few actually do. Legend Capital continues to add value beyond just capital. We are so lucky to have such a great partner as our investor."About Legend CapitalFounded in 2001, Legend Capital is a leading VC&PE investor focusing on the early-stage and growth-stage opportunities in China, with offices across Beijing, Shanghai, Shenzhen, Hong Kong, and Seoul, Korea.It currently manages USD and RMB funds of over US$10 billion in commitments, and has invested in around 600 companies, covering technology, healthcare, consumer, enterprise service and intelligent manufacturing sectors. Rooted in China, Legend Capital participated in the rise of many world-leading companies by solid investment coverage and systematic post-investment value-add. Over the years, Legend Capital has also become a widely recognized name in bridging key resources in China and overseas through cross-border activities, and a valuable partner to Chinese and overseas investors. Legend Capital values long-term sustainable investment and incorporates ESG into its long-term development strategy. As a UNPRI signatory since November 2019, Legend Capital is among the first group of top VC/PE firms in China to join the initiative. For more information, please visit www.legendcapital.com.cn/index_en.aspx and follow us on LinkedIn @Legend Capital (https://www.linkedin.com/company/legend-capital). Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

Led by Legend Capital, GS Biotech Completes Nearly CNY100 million Pre-A Round Financing

HONG KONG, Dec 9, 2022 - (ACN Newswire via SEAPRWire.com) - Recently, Zhongke Guosheng (Hangzhou) Technology Co., Ltd (hereinafter referred to as "GS Biotech") officially announced the completion of its nearly CNY100 million pre-A round financing, led by Legend Capital. The proceeds will be mainly used for the capacity expansion of core pipeline products 5-hydroxymethylfurfural (HMF), 2,5-furandicarboxylic acid (FDCA) and 2,5-tetrahydrofuran dimethanol (THFDM), and the continuous development of downstream derivatives.Founded in 2021 with the vision of "Biomass Change Lives", GS Biotech is a bio-based material and R&D company dedicated to building a bio-based material industry chain. The members of its founding team graduated from the Dalian Institute of Chemical Physics, Chinese Academy of Sciences, and have nearly 20 years of research foundation and industrialization experience in the fields of biomass catalytic conversion and furan-based material design and development. At present, the R&D team building has also been completed from biomass, derivatives to polymers, which ensures the cutting-edge of the company's product development and the availability of end products.According to Dr. John Zhang, CEO of GS Biotech, the company has taken the development model of promoting the "two-wheel drive" of the dual track as an important strategic direction. On the one hand, the company has completely solved the problems of HMF cost and raw material sources; its original HMF continuous production process, which completed the verification of multi-dimensional cost reduction measures, has greatly reduced the production cost and effectively improved the efficiency, and it is expected that the production cost of HMF will be controlled within RMB10,000 per ton in the future three years from the extraction of non-grain raw material sources to the iterative path of the production process and to the planning of expanding production capacity. Meanwhile, the company has also reserved more than 20 kinds of high-value-added monomers and is simultaneously promoting the verification of the application of each monomer in the terminal market. Moreover, GS Biotech established a joint venture, Xinshengtai Materials, with an AI-powered drug R&D unicorn company XtalPi Inc to focus on using AI technology to accelerate the reverse design of derivatives and improve the development efficiency of downstream derivatives to further accelerate its high-efficiency and accurate market development process.On the other hand, the company has also made significant progress in the design, R&D and industrialization of degradable new materials. The new biodegradable plastic PEOX, another important pipeline of the company, has completed the 150L pilot scale experiment and obtained market terminal verification. The performance indicators of PEOX can be compared with PGA and the price of the terminal product will be approximately RMB10,000/ton after the large-scale production. With the special performance of the product and the support of policies, many leading enterprises in the industry are negotiating with the company to sign an underwriting agreement to apply PEOX in the field of disposable packagings such as agricultural mulch, plastic bags, straws, and lunch boxes.Legend Capital said: "Under the background of China's strategy in carbon peaking and carbon neutrality and the pursuit of sustainable energy development, petroleum-based chemical materials will gradually be replaced by bio-based materials, which are produced from sustainable resources. HMF is an important bio-based platform compound with great potential for downstream derivatives. GS Biotech has pioneered the HMF continuous production process globally and realized the large-scale and low-cost production of HMF. It has opened the entire industry chain from upstream core monomers to terminal applications and innovatively introduced AI and high-throughput machine synthesis technology into the development of downstream derivative products. The core team of GS Biotech graduated from the Dalian Institute of Chemical Physics of the Chinese Academy of Sciences. With nearly 20 years of research foundation and industrialization experience in the field of biomass catalytic conversion, GS Biotech has shown strong capabilities in continuous R&D, production management, and resource integration. Legend Capital has long focused on technology investments linked to carbon peaking and carbon neutrality, and we look forward to working with GS Biotech to promote technological change in the field of bio-based materials."As an interdisciplinary subject of information science, life science and material science, synthetic biology and bio-based materials have always been the direction that Legend Capital has paid close attention to in the field of carbon-neutral technology investment. Legend Capital's investments in the carbon-neutral field focus on energy decarbonization, vehicle electrification/intelligence, synthetic biology, etc. Energy decarbonization includes photovoltaic, wind power, and smart grid; vehicle electrification/intelligence includes lithium battery vehicles, hydrogen fuel cell vehicles, battery recycling and others; in the field of synthetic biology and bio-based materials, Legend Capital has invested in many outstanding companies such as Giant Biogene (02367.HK), GS Biotech, Huili Biotech, and Tidetron Bioworks Technology.About Legend CapitalFounded in 2001, Legend Capital is a leading VC&PE investor focusing on the early-stage and growth-stage opportunities in China, with offices across Beijing, Shanghai, Shenzhen, Hong Kong, and Seoul, Korea.It currently manages USD and RMB funds of over US$10 billion in commitments, and has invested in around 600 companies, covering technology, healthcare, consumer, enterprise service and intelligent manufacturing sectors. Rooted in China, Legend Capital participated in the rise of many world-leading companies by solid investment coverage and systematic post-investment value-add. Over the years, Legend Capital has also become a widely recognized name in bridging key resources in China and overseas through cross-border activities, and a valuable partner to Chinese and overseas investors. Legend Capital values long-term sustainable investment and incorporates ESG into its long-term development strategy. As a UNPRI signatory since November 2019, Legend Capital is among the first group of top VC/PE firms in China to join the initiative. For more information, please visit www.legendcapital.com.cn/index_en.aspx and follow us on LinkedIn @Legend Capital (https://www.linkedin.com/company/legend-capital). Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

续获新鸿基公司支持   E15VC完成第三只基金首轮募资

EQS 新闻 via SEAPRWire.com / 2022-12-06 / 17:18 UTC+8 续获新鸿基公司支持   E15VC完成第三只基金首轮募资   环球科技创投公司E15VC宣布，推出第三只基金E15 Fund III, LP（简称「该基金」），并完成首轮募资，募资额为6,075万美元。该基金的期限为十年，专注于投资全球深度科技机遇。   该基金获新鸿基有限公司（香港交易所股票代号：86，简称「新鸿基公司」）锚定及大力支持，并透过新鸿基公司旗下的另类基金管理平台Sun Hung Kai Capital Partners Limited（简称「SHKCP」）执行伙伴合作关系。   E15VC首只和第二只基金专注投资于解决科技、医疗保健和深度技术等重大议题的企业，并取得了骄人成绩。这家香港公司已投资于许多创新企业，包括Eikon Therapeutics、Frankie、Celebrity Agent、Caeli Vascular，并且已经成功退出了对Vicarious Surgical和Auris Health的投资。   E15VC行政总裁李祚然(Ted Lee)表示：「我们团队对于本基金首轮募资感到自豪，衷心感谢投资者在充满挑战的市场环境下仍然对我们投下信心的一票，我们希望以卓越的投资机遇和回报，报答他们的信任。」   E15VC管理合伙人梁世杰(Philip Liang)补充指：「团队期待可以继续发掘、投资和支持有使命感的企业家，并帮助他们实现下一阶段的成长。E15VC第三只基金代表了我们成长进程的一个重要里程碑。」   新鸿基公司与E15VC的伙伴合作关系始于在E15VC第二只基金募资时投入了种子资金，并于第三只基金继续对其支持。   SHK Capital Partners行政总裁琳熙(Lindsay Wright)表示：「我们很高兴伙拍E15VC推出第三只基金。我们对E15VC物色全球领先企业和执行投资项目的能力继续充满信心，新鸿基对于作为这个优秀团队的合作伙伴感到自豪。」   新鸿基公司是一家领先的金融服务与另类投资机构。公司正通过注入种子资金、分销和提供加速资本以拓展其另类基金管理平台SHK Capital Partners与外部合作关系。        关于新鸿基有限公司   新鸿基有限公司（香港交易所股票代号：86）是一家领先的另类投资金融企业，总部位于香港。建基于1969年，集团一直拥有及经营行业领先的金融服务平台。集团的投资涵盖公开市场、另类投资及房地产，并于为股东缔造长期经风险调整回报上拥有良好往绩。最近，集团拓展其策略，发掘、推动及支持亚洲地区的新晋资产管理公司。集团亦是领先的消费金融公司——亚洲联合财务有限公司的大股东。截至2022年6月30日，集团资产总值约为490亿港元。   如欲了解更多公司信息，请浏览企业网站www.shkco.com。       关于E15VC   E15VC是在2017年由梁世杰(Philip Liang)于香港成立，是一支由工程师和企业家组成的团队，在科学和技术领域取得了不少重要成果，在培育及退出投资组合也拥有良好的往绩，目前退出公司包括：Auris Health（已出售予J&J）和Vicarious Surgical（纽约证券交易所代码：RBOT）。 如欲了解更多有关E15VC的信息，请浏览公司网站https://e15vc.com/。           如有垂询，请联络伟达公共关系顾问： 林贵珍 / 关颖欣 电话：(852) 2894 6211 / (852) 2894 6275 电邮：SHKCo@hkstrategies.com   文件: 续获新鸿基公司支持   E15VC完成第三只基金首轮募资 2022-12-06 此财经新闻稿由EQS Group via SEAPRWire.com转载。本公告内容由发行人全权负责。原文链接: http://www.todayir.com/sc/index.php

Read More
Posted on

Legend Capital Portfolio Company Atour Successfully Lists on Nasdaq

HONG KONG, Nov 13, 2022 - (ACN Newswire via SEAPRWire.com) - On the evening of November 11, Beijing time, Legend Capital portfolio company Atour Lifestyle Holdings Limited ("Atour") was officially listed on the Nasdaq Stock Exchange in the United States. It has priced its initial public offering of 4,750,000 American Depositary Shares ("ADSs") at US$11.0 per ADS.Founded in 2013, Atour is a leading hospitality and lifestyle company in China with a distinct portfolio of lifestyle hotel brands, such as A.T. HOUSE, Atour S, ZHOTEL, Atour Hotel, Atour X and Atour Light, as well as scenario-based retail brands, including Atour Market. It has further divided its private labels into three product lines - aTOUR PLANET, SAVHE and Z2GO&CO. As of June 30, 2022, Atour has launched a total of 1,967 SKUs, 62.8% of which are private-label products. According to the prospectus, as of September 30, 2022, Atour has opened 880 hotels, a year-on-year increase of 26%. According to Frost & Sullivan, Atour is the largest upper midscale hotel chain with a diversified brand portfolio in China in terms of room numbers for five consecutive years as of the end of 2021. As an important institutional investor and close partner of Atour, Legend Capital led the investment in Atour in 2016, and continued to make additional investments in Atour's subsequent financing rounds in 2017 and 2021. Following the investment, Legend Capital has continuously supported Atour's development by providing multiple value-added services in terms of development strategy, corporate governance and incentive mechanism, listing work and business resources.Legend Capital said: " The past nine years have witnessed Atour's continuous development since its first hotel opening in 2013. Looking back at the development of China's hotel industry over the past decade, Atour is the only company with precise positioning and bringing changes to China's hotel industry. It has brought a new service standard to the industry. It is also a lifestyle consumer brand providing a warm and happy feeling that can be remembered by customers. Atour's founder and the team are rare talents in the domestic hotel industry. The team is dynamic and young, with over ten years of operating experience in the hotel industry. The listing marks a new milestone for Atour. It is not only an affirmation of the past achievements of Atour, but also an acknowledgment of their tenacity and professionalism. This also reflects the expectation for the future innovation and development of Atour. As Atour's investor, we are proud to be able to participate in and witness its growth."About Legend CapitalFounded in 2001, Legend Capital is a leading VC&PE investor focusing on the early-stage and growth-stage opportunities in China, with offices across Beijing, Shanghai, Shenzhen, Hong Kong, and Seoul, Korea.It currently manages USD and RMB funds of over US$10 billion in commitments, and has invested in around 600 companies, covering technology, healthcare, consumer, enterprise service and intelligent manufacturing sectors. Rooted in China, Legend Capital participated in the rise of many world-leading companies by solid investment coverage and systematic post-investment value-add. Over the years, Legend Capital has also become a widely recognized name in bridging key resources in China and overseas through cross-border activities, and a valuable partner to Chinese and overseas investors. Legend Capital values long-term sustainable investment and incorporates ESG into its long-term development strategy. As a UNPRI signatory since November 2019, Legend Capital is among the first group of top VC/PE firms in China to join the initiative. For more information, please visit www.legendcapital.com.cn/index_en.aspx and follow us on LinkedIn @Legend Capital (https://www.linkedin.com/company/legend-capital). Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

Led by Legend Capital, PureFDA Secures Over CNY100 million in the Series B Round

HONG KONG, Nov 10, 2022 - (ACN Newswire via SEAPRWire.com) - Recently, PureFDA Medical Technology (Guangzhou) Co., LTD. (hereinafter referred to as "PureFDA") announced the completion of the Series B round of financing of over CNY100 million, which was led by Legend Capital and followed by the existing shareholder Bayland Capital. This round of funds will mainly be used for the construction of overseas medical device resources, the expansion of the professional talent team, the strategic expansion of the medical devices field, and the upgrading and iteration of the big data information platform.Founded in June 2020, PureFDA is a global-leading SaaS + Data service life science service provider that focuses on whole-process informatization of medical devices going overseas in the global market. Besides, the company is dedicated to providing whole-process consulting services for compliance access to the global market for products such as medical devices, in vitro diagnostics and medical software AI, covering device regulations consultation, local authorized representatives, product certification and registration, overseas clinical trials, technical documentation and system guidance, product testing, etc.Relying on its top-notch expert team with regulatory certification and extensive clinical experience, PureFDA provides one-stop solutions such as whole-process consulting services for compliance access to the global market and overseas clinical trials. The company's service network has spread to 10 countries and regions worldwide, including the United States, Germany, Italy, Spain, Switzerland and Poland. Moreover, it has been doing business with over 100 Chinese and international medical and biotech companies and has been widely recognized by industry insiders. PureFDA has 8 branch companies and possesses scarce clinical resources in the industry. Its overseas clinical centers in Europe and the United States have been certified with qualifications such as CLIA, CAP and ISO 17025.Regarding this financing, MENG Zhu, the founder of PureFDA, said, "Our original intention is to help Chinese medical device enterprises go overseas and expand overseas clinical resources. With 10 major clinical centers, we are committed to creating a one-stop and full-chain service ecosystem. Through the accumulation of experience in the field of computer technology and big data, we empower medical innovation by using the new generation of information technology to establish a standardized and digital system for medical devices going overseas. With the professional consulting service for multinational medical device market access and high-quality overseas clinical resources, PureFDA is capable of meeting the needs of Chinese medical device enterprises for cross-border registration of CROs in multiple countries and categories. PureFDA's development is inseparable from the strong support of new and existing shareholders and customer partners. With the fresh proceeds, we will continue to upgrade the global regulation intelligence platform and help medical device enterprises license-out their products by providing data services such as trade analysis, overseas dealer network and clinical trend research."Joe ZHOU, managing director of Legend Capital, said: "Going overseas has become a consensus in the development of China's medical device enterprises, but it also faces a series of difficulties and challenges, of which the sore points are mainly concentrated in the access and marketing to the overseas market. With the increasing tightening of global device regulations, it is difficult, costly, long cycle, low efficiency and low success rate for enterprises to independently complete overseas access, leading a great need for the assistance of CRO service providers who focus on going overseas. However, the traditional expert CRO services are difficult to meet the diversified demands of the highly dispersed downstream device enterprises for their products to go overseas, and the scale effect and profitability of CRO enterprises also encounter bottlenecks. With its rich overseas clinical resources and new digital CRO services driven by data and algorithms, PureFDA has successfully achieved cross-country, cross-department and cross-category CRO capabilities, as well as significant advantages in cost reduction and efficiency enhancement. PureFDA is a company expected to break the bottleneck of traditional device CRO enterprises and bring disruptive changes in the equipment CRO industry."About Legend CapitalFounded in 2001, Legend Capital is a leading VC&PE investor focusing on the early-stage and growth-stage opportunities in China, with offices across Beijing, Shanghai, Shenzhen, Hong Kong, and Seoul, Korea. It currently manages USD and RMB funds of over US$10 billion in commitments, and has invested in around 600 companies, covering technology, healthcare, consumer, enterprise service and intelligent manufacturing sectors. Rooted in China, Legend Capital participated in the rise of many world-leading companies by solid investment coverage and systematic post-investment value-add. Over the years, Legend Capital has also become a widely recognized name in bridging key resources in China and overseas through cross-border activities, and a valuable partner to Chinese and overseas investors. Legend Capital values long-term sustainable investment and incorporates ESG into its long-term development strategy. As a UNPRI signatory since November 2019, Legend Capital is among the first group of top VC/PE firms in China to join the initiative. For more information, please visit www.legendcapital.com.cn/index_en.aspx and follow us on LinkedIn @Legend Capital (https://www.linkedin.com/company/legend-capital). Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

Legend Capital Portfolio Company Giant Biogene Successfully Lists on the HKEX

HONG KONG, Nov 7, 2022 - (ACN Newswire via SEAPRWire.com) - On November 4, 2022, Legend Capital portfolio company Giant Biogene (2367.HK) was successfully listed on the main board of the Hong Kong Stock Exchange. The number of Giant Biogene's offer shares under the global offering is 22,608,800 shares at an issue price of HK$24.3 per share, which includes 2,261,200 Hong Kong offering shares, 20,347,600 international offering shares, as well as a 15% over-allotment option.Giant Biogene is a leader in the bioactive ingredient-based professional skin treatment product industry in China and the first company in the world to successfully develop and industrialize recombinant collagen skin treatment products. Giant Biogene has been the largest collagen-based professional skin treatment product company by retail sales in China for the latest three consecutive years since 2019. According to Frost & Sullivan, Giant Biogene was the second-largest professional skin treatment product company in China in 2021, and its Collgene and Comfy, the flagship brands of recombinant collagen-based products, were the third and the fourth best-selling professional skin treatment brands, respectively. Giant Biogene is the first company to obtain a medical device registration for recombinant collagen-based products in China.Legend Capital participated in Giant Biogene's only round of financing in 2021. Following the investment, Legend Capital provided Giant Biogene value-added services on core issues such as business strategy discussion, upstream and downstream business resource docking, executive talent introduction, and IPO listing process.Richard LI, President of Legend Capital, said: "Congratulations to Giant Biogene on its successful listing on the main board of the Hong Kong Stock Exchange. Legend Capital is very honored to be an investor in Giant Biogene and to carry out in-depth investment cooperation with the company. With 22 years of development and unremitting efforts under the leadership of the company's management, Giant Biogene has achieved excellent results and has become a pioneer enterprise in the field of biosynthetic materials and products in China. We hope that Giant Biogene will make steady progress and achieve greater achievements in the future development and continue to brave the wind and the waves in the changing market."Tony WANG, Managing Director of Legend Capital, said: "Giant Biogene is a pioneer in the synthetic biology industry. It not only builds a leading technology platform for genetic engineering, tissue engineering and material engineering but also applies scientific research results to the field of healthcare. Giant Biogene demonstrated the best practice out of the combination of production, education and research. We look forward to this diligent and pragmatic team continuing to go forward and leading Chinese brands to the international market in the future." About Legend CapitalFounded in 2001, Legend Capital is a leading VC&PE investor focusing on the early-stage and growth-stage opportunities in China, with offices across Beijing, Shanghai, Shenzhen, Hong Kong, and Seoul, Korea. It currently manages USD and RMB funds of over US$10 billion in commitments, and has invested in around 600 companies, covering technology, healthcare, consumer, enterprise service and intelligent manufacturing sectors. Rooted in China, Legend Capital participated in the rise of many world-leading companies by solid investment coverage and systematic post-investment value-add. Over the years, Legend Capital has also become a widely recognized name in bridging key resources in China and overseas through cross-border activities, and a valuable partner to Chinese and overseas investors. Legend Capital values long-term sustainable investment and incorporates ESG into its long-term development strategy. As a UNPRI signatory since November 2019, Legend Capital is among the first group of top VC/PE firms in China to join the initiative. For more information, please visit www.legendcapital.com.cn/index_en.aspx and follow us on LinkedIn @Legend Capital (https://www.linkedin.com/company/legend-capital). Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

Led by Legend Capital, ClinBrain Completes Nearly CNY200 million Series C Round

HONG KONG, Nov 1, 2022 - (ACN Newswire via SEAPRWire.com) - Recently, the healthcare big data leader ClinBrain completed the Series C round of financing of nearly CNY200 million, led by Legend Capital. This round of financing will facilitate ClinBrain to continuously deepen its expertise in the field of healthcare big data, explore the deep integration of big data and AI in the healthcare industry, promote the R&D of underlying technologies and scenario-based applications, and accelerate the promotion of industrial digital and intelligent upgrading.As a high-tech enterprise focusing on the healthcare big data intelligence platform, digitalized and intelligent application services, ClinBrain was shortlisted as the SDRI (specialized, refined, differential and innovative) "little giant" enterprise by the Ministry of Industry and Information Technology this year.At the beginning of its establishment in 2013, ClinBrain realized that healthcare, as a data-intensive and knowledge-intensive industry, is inseparable from the support of data, no matter in clinical services, operations management or medical research. ClinBrain has been committed to the direction of data governance and intelligent application of hospitals. By leveraging years of its industry experience and technical capabilities, the company has made breakthroughs in many fields, such as collecting data from hospital business systems without an interface, effectively identifying the data structure of complex business systems, effectively cleaning the business data of different versions and different manufacturers, forming effective and practical data quality rules to improve the data quality of hospitals, and conducting structured processing of unstructured data such as medical records and pathology. Moreover, with its powerful natural language processing (NLP) capabilities and robust rule and knowledge base, including more than 3900 data cleaning and quality rules embedded and tens of millions of medical concept term relationships accumulated, ClinBrain is also capable of automatically identifying the data structure of each version of more than 500 business manufacturers and realizing high-quality data cleaning and structured processing of unstructured data.LIU Huanchun, Chairman of ClinBrain, said, "Under the complex and volatile economic background and the ongoing pandemic situation, the recognition by many investors has reflected the market position, technological level and value of ClinBrain. After this round of financing, ClinBrain will promote the company's development to a new level by making further efforts in scientific and technological innovation and talent introduction."Raymond CHEN, Co-chief Investment Officer of Legend Capital, said, "Healthcare big data is a key driver of the digital and intelligent transformation of the pharmaceutical industry, which is in line with the long-term megatrend of new healthcare infrastructure. As a leading healthcare big data enterprise in China, ClinBrain provides full-link solutions from data governance to medical scenario applications based on its rich industrial theoretical knowledge and practical experience. We are optimistic that ClinBrain will create a new development form in healthcare big data by continuously expanding more products and customer application scenarios."About Legend CapitalFounded in 2001, Legend Capital is a leading VC&PE investor focusing on the early-stage and growth-stage opportunities in China, with offices across Beijing, Shanghai, Shenzhen, Hong Kong, and Seoul, Korea. It currently manages USD and RMB funds of over US$10 billion in commitments, and has invested in around 600 companies, covering technology, healthcare, consumer, enterprise service and intelligent manufacturing sectors. Rooted in China, Legend Capital participated in the rise of many world-leading companies by solid investment coverage and systematic post-investment value-add. Over the years, Legend Capital has also become a widely recognized name in bridging key resources in China and overseas through cross-border activities, and a valuable partner to Chinese and overseas investors. Legend Capital values long-term sustainable investment and incorporates ESG into its long-term development strategy. As a UNPRI signatory since November 2019, Legend Capital is among the first group of top VC/PE firms in China to join the initiative. For more information, please visit www.legendcapital.com.cn/index_en.aspx and follow us on LinkedIn @Legend Capital (https://www.linkedin.com/company/legend-capital). Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

Led by Legend Capital, Easy-Flow Raises Tens of Millions of CNY in Angel Round

HONG KONG, Nov 1, 2022 - (ACN Newswire via SEAPRWire.com) - Shanghai Easy-Flow ("Easy-Flow") recently completed its Angel financing round by raising tens of millions of CNY, led by Legend Capital. The fresh capital will be used for the R&D of Easy-Flow's peripheral intervention pipeline.Data shows that there are a large number of patients with peripheral vascular disease, of which about 40 million patients with lower extremity arteries and about 100 million patients with varicose veins. Given the number of patients is increasing yearly, there is a huge clinical demand foreseeable, indicating that the peripheral vascular interventional device trajectory is likely to be the next market worth CNY10 billion.Founded in November 2021, Easy-Flow is committed to efficiently creating a complete set of solutions in the field of peripheral interventional devices. The company develops products such as drug balloons, catheters, stents, and thrombus removal equipment for treating peripheral arteriovenous diseases. Since its establishment, Easy-Flow has been committed to creating peripheral interventional product packages, and developing Me-too, Me-better and Me-only products at the same time. It is expected that several products will be submitted for registration or initiated into clinical practice by 2030.In addition to its independent R&D, Easy-Flow also simultaneously carries out external cooperation to further expand its product pipeline. Easy-Flow recently has reached a cooperation with Control Medical in the United States to introduce the FDA-approved Control(TM) mechanical thrombus removal system, which can be manually controlled by doctors to achieve efficient and controllable thrombus aspiration.The founder of Easy-Flow, MIAO Zhenghua, who has more than 20 years of experience in the field of vascular intervention, said: "At present, the biggest challenge to many startups is how to rapidly commercialize their certified products. On the one hand, many founders have R&D backgrounds but lack experience in marketing their products quickly, and some companies only focus on one or two items, making them hard to cover marketing expenses with their revenue and profits. On the other hand, there are many product categories in the field of peripheral interventional devices. The treatment of disease often requires multiple products, and it is difficult to support the market with a single product. Therefore, the integrated package of peripheral interventional products is more suitable for commercial promotion."Regarding this financing round, Joe ZHOU, managing director of Legend Capital, said: " Legend Capital has long focused on investment in medical devices. We have invested in a number of companies focusing on the unmet clinical needs of major diseases, especially chronic diseases. Cardiovascular and cerebrovascular-related fields have always been the focus of systematic analysis and research of the Legend Capital team. Easy-Flow has a talent team with extensive experience, led by the founder MIAO Zhenghua. We are very pleased to cooperate with Easy-Flow and participate in the development of the company. In the future, Legend Capital will give full play to the advantages of the healthcare portfolio ecosystem to support Easy-Flow's development and move forward hand in hand."About Legend CapitalFounded in 2001, Legend Capital is a leading VC&PE investor focusing on the early-stage and growth-stage opportunities in China, with offices across Beijing, Shanghai, Shenzhen, Hong Kong, and Seoul, Korea. It currently manages USD and RMB funds of over US$10 billion in commitments, and has invested in around 600 companies, covering technology, healthcare, consumer, enterprise service and intelligent manufacturing sectors. Rooted in China, Legend Capital participated in the rise of many world-leading companies by solid investment coverage and systematic post-investment value-add. Over the years, Legend Capital has also become a widely recognized name in bridging key resources in China and overseas through cross-border activities, and a valuable partner to Chinese and overseas investors. Legend Capital values long-term sustainable investment and incorporates ESG into its long-term development strategy. As a UNPRI signatory since November 2019, Legend Capital is among the first group of top VC/PE firms in China to join the initiative. For more information, please visit www.legendcapital.com.cn/index_en.aspx and follow us on LinkedIn @Legend Capital (https://www.linkedin.com/company/legend-capital). Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

Co-Led by Legend Capital, Top Gene Delivery Enterprise VectorBuilder Secures CNY410mn in Series C Round

HONG KONG, Oct 20, 2022 - (ACN Newswire via SEAPRWire.com) - VectorBuilder Biotechnology (Guangzhou) Co., Ltd. (hereinafter referred to as "VectorBuilder"), a top gene delivery enterprise, recently announced the completion of its Series C round with CNY410 million, co-led by Legend Capital. The proceeds will facilitate VectorBuilder in continuously promoting the upgrading and capacity expansion of the gene delivery R&D and production technology platform, further accelerate the global business presence, and boost the R&D of life sciences and genetic medicines. VectorBuilder was founded by Dr. Bruce Lahn, a world-renowned molecular biologist who was a tenured professor at the University of Chicago and a researcher at Howard Hughes Medical Institute (HHMI). The company provides services such as scientific research and clinical carrier CRO, gene-drug CDMO and gene delivery IP out-licensing, covering the entire field of life science and gene medicine. VectorBuilder has provided more than 1.2 million gene delivery solutions to more than 4,000 scientific research institutes and pharmaceutical companies worldwide, and its gene-drug CRO and CDMO projects are spread all over North America, Europe, Japan and South Korea.Dr. Bruce Lahn, Founder and Chief Scientist of VectorBuilder, said: "I'd like to take this opportunity to extend my sincere gratitude to investors for the support and trust. Due to a robust technical accumulation and an excellent business model in the gene delivery industry, VectorBuilder enjoys the highest market share in the global gene carrier scientific research market, and we jointly launched the construction of a 45,000-square-meter gene delivery R&D and production base with Guangzhou Development District Investment Group in April 2022. We hope to take this financing round as an opportunity to further accelerate the comprehensive upgrade and optimization of the technology platform and promote the expansion of production capacity and global presence. VectorBuilder has become a pioneer in the entire gene delivery industry chain by empowering basic scientific research and accelerating the clinical application of gene drugs. We believe VectorBuilder will enter thousands of life science laboratories worldwide and become a well-known brand in the field of life science. We will empower the gene-drug industry through core technologies and help China to "overtake" on the genetic drug track. At the same time, we hope to overcome genetic diseases, improve human health, and provide irreplaceable value to the industry and the world."Jeff Wang, Managing Director of Legend Capital, said: "VectorBuilder is the world's leading gene delivery company, providing full-chain solutions from basic scientific research to clinical application of gene delivery. It is an honor to participate in the future development of VectorBuilder. Dr. Bruce Lahn is an expert in the field of biotechnology innovation, and we are optimistic about VectorBuilder's comprehensive ecological service platform for gene delivery in life science and biomedicine. VectorBuilder has developed the world's first system providing online design, offline production carrier construction and downstream application service, serving thousands of top biopharmaceutical companies and research institutes. We believe VectorBuilder has a promising future as the genetic medicine industry develops." About Legend CapitalFounded in 2001, Legend Capital is a leading VC&PE investor focusing on the early-stage and growth-stage opportunities in China, with offices across Beijing, Shanghai, Shenzhen, Hong Kong, and Seoul, Korea. It currently manages USD and RMB funds of over US$10 billion in commitments, and has invested in around 600 companies, covering technology, healthcare, consumer, enterprise service and intelligent manufacturing sectors. Rooted in China, Legend Capital participated in the rise of many world-leading companies by solid investment coverage and systematic post-investment value-add. Over the years, Legend Capital has also become a widely recognized name in bridging key resources in China and overseas through cross-border activities, and a valuable partner to Chinese and overseas investors. Legend Capital values long-term sustainable investment and incorporates ESG into its long-term development strategy. As a UNPRI signatory since November 2019, Legend Capital is among the first group of top VC/PE firms in China to join the initiative. For more information, please visit www.legendcapital.com.cn/index_en.aspx and follow us on LinkedIn @Legend Capital (https://www.linkedin.com/company/legend-capital). Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

The Next Vision Capital Announces an Investment from IDG Capital Blockchain

Hanoi, Vietnam, October 17, 2022 – (SEAPRWire) – Recently, the Next Vision Capital, a digital financial platform offering packages to SMEs, is proud to announce an Investment from IDG Capital Blockchain (IDGCB). IDG Capital Blockchain currently manages 40 million dollars and has been investing in over 30 companies under various sectors. Having found the potential of Next Vision Capital (NVC) in the blooming age of Blockchain related technology, IDGCB has made the decision to invest in NVC. Applying blockchain and AI technology to build a financial platform, NVC built a vision to drive the global fund flows to the developing economies, where businesses are thirsty. NVC offers flexible packages to help businesses overcome financial struggles and develop sustainably. Moreover, the team is researching and developing the NFT platform, which applies blockchain technology for SEA SMEs to call for global investment. NVC partners with local banks, using their process of lending out and debt return to check borrower credit before offering the loans. Furthermore, the company cooperates with local insurance firms to secure the bad debts. NVC is gaining trust on the stable business model and attracting investors from over the world. On 6th October 2022, NVC held the Next Vision Capital Investment Show at Suntec Convention & Exhibition Center, to connect with investors in Singapore. More than 100 SEA investors are excited to join and follow up with NVC’s vision.  This event marked the first milestone of NVC in the global roadmap. The company has received a committed budget of 30 million USD from Investors to provide loan packages for regional SMEs through NVC lending platform in the next 18 months. NVC constantly endeavors to look for potential funds from global investors with the tempting interest rate. Social Links Facebook: https://www.facebook.com/profile.php?id=100086478185794 Media Contact Brand: The Next Vision Capital Contact: Media team Email: contact@thenvcgroup.com Website: http://thenvcgroup.com/ SOURCE: The Next Vision Capital The article is provided by a third-party content provider. SEAPRWire ( https://www.seaprwire.com/ ) makes no warranties or representations in connection therewith. Any questions, please contact cs/at/SEAPRWire.com Sectors: Top Story, Daily News SEA PRWire: PR distribution in Southeast Asia (Hong Kong: AsiaExcite, EastMud; AsiaEase; Singapore: SEAChronicle, VOASG; NetDace; Thailand: SEAsiabiz, AccessTH; Indonesia: SEATribune, DailyBerita; Philippines: SEATickers, PHNotes; Malaysia: SEANewswire, KULPR; Vietnam: SEANewsDesk, PostVN)

Read More
Posted on

Indonesia to offer 80/160-year building (HGB) permits in IKN Nusantara to incentivise investment

JAKARTA, Oct 14, 2022 - (ACN Newswire via SEAPRWire.com) - Indonesia's Ministry of Agrarian Affairs and Spatial Planning/National Land Agency (ATR/BPN) is offering building use permits (HGBs) of up to 80 years, extendable to 160 years, as an incentive for investors to join in the construction of the Indonesian new capital (IKN) Nusantara, to be built in Samarinda, East Kalimantan.Balang Island Short Span Bridge connecting the IKN in Penajam, North Paser Regency, East Kalimantan (ANTARA/HO-ATR BPN/rst)Minister of Agrarian & Spatial Planning (ATR) and head of National Land Agency (BPN), Hadi Tjahjanto. (ANTARA/HO-ATR BPN/rst)"The HGB permits will benefit all parties, both the welfare of those who live in the city, and the business actors themselves," ATR Minister and BPN head Hadi Tjahjanto said to Antara here on Monday. The 80-year HGB will be divided into three stages: the first phase will span 30 years, the second phase 30 years, and the third phase 20 years.During the first stage, the investor must submit an assessment report, after which the "The permit will continue up to 80 years," said Hadi, and can be extended if it is productive for the community. "If it is still used properly and beneficially for the community, we can still extend it for another 80 years, up to 160 years," the minister informed.He further said that his ministry has completed four regional spatial planning plans (RDTR) for IKN Nusantara, which will be submitted to the IKN Authority for immediate approval. Furthermore, RDTRs are being prepared for the five regions of IKN Nusantara and are targeted to be completed by the end of 2022.The ministry will provide facilities related to land, spatial planning, and business licensing in the IKN Nusantara area, which will then be submitted to the IKN Authority. "We will facilitate it, and we will hand it over to the head of the IKN Authority, including RDTR, spatial planning, and land issues. We will help the process," Hadi said.The IKN Nusantara Authority is preparing a government regulation draft (RPP) on incentives for business, to make it easier to invest in the new capital city, while another measure will be preparing an IKN Authority-owned enterprise (BUMO). The IKN Authority will carry out market sounding of domestic and international investors later in October.A number of Asian countries have shown interest in the development of the new Indonesian capital (IKN) Nusantara. Japan, China, Malaysia, Australia, Hong Kong, and South Korea have all evinced an interest in investment, East Kalimantan Governor Isran Noor has disclosed.Earlier this year, President Joko Widodo said, "The new capital city is not merely a move of government offices. The goal is to build a new smart city that is competitive at the global level. Building a new locomotive for the transformation of Indonesia into an Indonesia based on innovation, technology, green economy. This is where we will start." See the original article: https://en.antaranews.com/news/254193/Written by: Rini Utami, Aditya Ramadhan, Resinta S, Editor: Suharto (c) ANTARA 2022 Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

AIM Vaccine, a Major Player in the Chinese Vaccine Industry Successfully Listed on the Main Board of SEHK

HONG KONG, Oct 6, 2022 - (ACN Newswire via SEAPRWire.com) - AIM Vaccine Co., Ltd. ("AIM Vaccine" or the "Company", together with its subsidiaries, the "Group", stock code: 06660.HK), the second largest vaccine company in China in terms of 2021 approved lot release volume (excluding COVID-19 vaccines), was successfully listed and commenced trading on the Main Board of The Stock Exchange of Hong Kong Limited ("SEHK") today, with a board lot of 200 H shares each. The debut of AIM Vaccine's stock price was very outstanding on 6 October. The share price closed at HK$16.66, up 3.09%.Goldman Sachs (Asia) L.L.C., China International Capital Corporation Hong Kong Securities Limited, China Securities (International) Corporate Finance Company Limited and Macquarie Capital Limited are the Joint Sponsors, Joint Global Coordinators, Joint Bookrunners and Joint Lead Managers. BOCI Asia Limited, CMB International Capital Limited, Futu Securities International (Hong Kong) Limited, and Tiger Brokers (HK) Global Limited are the Joint Bookrunners and Joint Lead Managers. ICBC International Capital Limited is Joint Bookrunner, ICBC International Securities Limited and Livermore Holdings Limited are the Joint Lead Managers.The Company said that the listing of AIM Vaccine in Hong Kong marks a key milestone and unfolds a new chapter in the Company's development. Looking ahead, AIM Vaccine will continue to strive to access to quality industry resources to expand and optimize its business. The Company will keep abreast of the most advanced platform technologies and innovation trends, accelerating the development of vaccine candidates and continuing to enrich its product portfolio, solidifying and expanding market leadership by increasing sales and marketing efforts for approved vaccine products and commercializing new products, thereby realizing its mission to "develop and manufacture top quality vaccines to safeguard the health of the world", becoming a world-class vaccine company in the global vaccine market and creating greater value for shareholders. Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

My Platform Joint Venture Awarded the Winner’s Prize in the 2022 Hong Kong-Macau-Taiwan Innovation and Entrepreneurship Competition

HONG KONG, Sep 29, 2022 - (ACN Newswire via SEAPRWire.com) - My Platform, the MedTech venture in which Black Spade Capital Limited ("Black Spade Capital") invested, has just announced that its PRC joint venture My Platform Information Technology (Guangzhou) Limited ("My Platform MedTech") was awarded the Winner's Prize in the 2022 Hong Kong-Macau-Taiwan Innovation and Entrepreneurship Competition organised by the Guangzhou Municipal Science and Technology Bureau. (1st from the Right) Mr. Jesse Ho, Chief Executive Officer of My PlatformThe competition brings together 226 participants from a wide variety of industries to honour the key players from Hong Kong, Macau and Taiwan for their achievement in the innovative and technology areas. My Platform MedTech ranked top 16 among the companies who received the award.My Platform MedTech is a joint venture established by My Platform and its partner in Guangzhou in 2021. It provides cloud-based services and doctor-patient community chatroom with telemedicine functions to hospitals and helps build an enclosed communication system between doctors and patients, which strengthens the connection between different specialist departments with patients and increases patient stickiness.In view of the growing demand for distant medical consultation, My Platform upgraded its system with telemedicine capabilities in 2020. This built-in function enables integration with other features thus offering a seamless and user-friendly experience.Mr. Jesse Ho, CEO of My Platform, said: "we are incredibly honoured to receive this award. It's a reflection of our team effort and the impact that we and our partners are making in the implementation of various initiatives to drive the technology development in the medical industry in the Greater Bay Area. We will continue with our good work to improve greater efficiency and better communication in the healthcare industry."About Black Spade Capital LimitedBlack Spade Capital Limited is an established family office managing the private investments of Mr. Lawrence Ho. Headquartered in Hong Kong, its global portfolio consists of a wide spectrum of cross-border investments as it consistently seeks to add new projects and opportunities to its investment mix. Black Spade Capital's investment strategy maximises coverage of geographic regions and sectors whilst maintaining a portfolio of diversified asset classes, ranging from equity, fixed income, pre-IPO investments, medical technology, leisure and culture, green energy, real estate to Web3. In July 2021, Black Spade Acquisition Co (NYSE: BSAQ), a special purpose acquisition company of which a subsidiary of Black Spade Capital is sponsor, was listed on the New York Stock Exchange.About My Platform Information Technology (Guangzhou) LimitedMy Platform is a global multi-party interactive cloud-based SaaS platform that provides a seamless experience in the healthcare industry for professionals and end-users. With over 20 years of experience in the medical, finance and IT fields, My Platform is dedicated to reshape the medical ecosystem and eliminate misinformation. Its powerful proprietary software can connect doctors, patients (members), pharmaceutical companies, insurance companies, hospitals and corporations and allows them to interact on one single platform. The all-integrated clinic solution built with state-of-the-art technology facilitates daily operation for all. Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

GalaxySpace Completes a New Financing Round with Legend Capital Re-upped

HONG KONG, Sep 25, 2022 - (ACN Newswire via SEAPRWire.com) - GalaxySpace, a Chinese commercial aerospace company, recently completed its latest financing round with a post-investment valuation of approximately RMB11 billion. As an existing shareholder, Legend Capital continued to support the company by following up on this financing round.Legend Capital first invested in GalaxySpace in 2018 and continued to follow up on the company's subsequent financing rounds in 2019, 2020 and 2022, increasing its investment layout of cutting-edge technology and supporting the development of GalaxySpace.Founded in 2018, GalaxySpace is the first unicorn enterprise in the field of commercial aerospace and satellite internet in China. Xu Ming, founder, chairman and CEO of GalaxySpace, said: "This round of financing will be mainly used for the R&D of satellite Internet-related technologies and the development of commercial applications. GalaxySpace will accelerate the R&D of core technologies such as stackable flat panel satellites, flexible multi-beam phased array technology, flexible solar wings, digital processing payloads, etc., and also the construction of mass-producing low-cost satellites. Step by step, we will move forward to the 6G era of the Internet of Everything."Nowadays, global space infrastructure construction has been developing rapidly, and commercial aerospace is becoming one of the new driving forces of the world's economic development. According to a Morgan Stanley report, the global space economy is expected to be worth $1 trillion by 2040, and the satellite Internet is expected to account for 50% or even 70% of the market growth.At present, GalaxySpace's new-generation stackable flat-panel satellite has entered the prototype development stage, which is also the first flat-panel satellite in China and will be launched early next year. It is believed that the development of stackable flat-panel satellites will promote the mass production of satellites and the rapid deployment of large-scale constellations. In the future, GalaxySpace will seize the development opportunities and fully utilize the advantages of small wins and rapid iteration of commercial aerospace to make a continuous innovative contribution to China's satellite Internet construction.About Legend CapitalFounded in 2001, Legend Capital is a leading VC&PE investor focusing on the early-stage and growth-stage opportunities in China, with offices across Beijing, Shanghai, Shenzhen, Hong Kong, and Seoul, Korea. It currently manages USD and RMB funds of over US$10 billion in commitments, and has invested in around 600 companies, covering technology, healthcare, consumer, enterprise service and intelligent manufacturing sectors. Rooted in China, Legend Capital participated in the rise of many world-leading companies by solid investment coverage and systematic post-investment value-add. Over the years, Legend Capital has also become a widely recognized name in bridging key resources in China and overseas through cross-border activities, and a valuable partner to Chinese and overseas investors. Legend Capital values long-term sustainable investment and incorporates ESG into its long-term development strategy. As a UNPRI signatory since November 2019, Legend Capital is among the first group of top VC/PE firms in China to join the initiative. For more information, please visit www.legendcapital.com.cn/index_en.aspx and follow us on LinkedIn @Legend Capital (https://www.linkedin.com/company/legend-capital). Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

Leadrive Technology Completes Series C Financing, Legend Capital Re-upped

HONG KONG, Sep 25, 2022 - (ACN Newswire via SEAPRWire.com) - Leadrive Technology, a leading supplier of power semiconductor and motor control solutions for new energy vehicles, recently announced its completion of the series C financing. As the existing shareholder, Legend Capital continued to support this round of financing.This round of financing will be mainly used for the construction of the IGBT/SiC power module packaging production line, the operation of the rapid production of motor control products, and the R&D of the latest generation of silicon carbide power modules and motor control products.Founded in 2017, Leadrive Technology has been committed to the forward development and production of power semiconductor modules and high-performance motor control units, bringing high-quality electric power to global automotive enterprise customers and consumers. After five years of rapid development, Leadrive Technology is equipped with mature technology and product solutions in the power modules and motor control units. A variety of high-performance IGBT power modules and main-drive dual-motor controller products developed by Leadrive have been installed in several hybrid models of many OEMs, achieving mass shipments and fully entering the passenger car market. With many test indicators at the industry-leading level in vehicle testing, the silicon carbide motor controller independently developed by Leadrive has also been designated and recognized by many downstream customers in the global market. In the future, Leadrive will center on the two core electrification foundations of power semiconductor modules and motor control units, and continue to invest in advanced technology development, product platform iteration, capacity expansion, and other fields. By leveraging its technological advantages, Leadrive works with industry chain partners to empower the electrification trend of the automotive industry and make outstanding contributions to promoting the technological progress of the industry.Dr. Jie Shen, the CEO of Leadrive, said: "Currently, the company is in a critical stage of rapidly developing large-scale delivery. This round of financing will mainly be used for the construction and implementation of the company's power module packaging production line and the replenishment of working capital for multiple mass production projects. For the smooth delivery of this round of financing, I would like to thank all the new and existing shareholders for their trust and strong support. With pursuing excellence in our mind, we take it as our duty to promote the technological progress of the industry as well as to make a continuous innovative contribution to the development of the new energy vehicle industry in China." About Legend CapitalFounded in 2001, Legend Capital is a leading VC&PE investor focusing on the early-stage and growth-stage opportunities in China, with offices across Beijing, Shanghai, Shenzhen, Hong Kong, and Seoul, Korea. It currently manages USD and RMB funds of over US$10 billion in commitments, and has invested in around 600 companies, covering technology, healthcare, consumer, enterprise service and intelligent manufacturing sectors. Rooted in China, Legend Capital participated in the rise of many world-leading companies by solid investment coverage and systematic post-investment value-add. Over the years, Legend Capital has also become a widely recognized name in bridging key resources in China and overseas through cross-border activities, and a valuable partner to Chinese and overseas investors. Legend Capital values long-term sustainable investment and incorporates ESG into its long-term development strategy. As a UNPRI signatory since November 2019, Legend Capital is among the first group of top VC/PE firms in China to join the initiative. For more information, please visit www.legendcapital.com.cn/index_en.aspx and follow us on LinkedIn @Legend Capital (https://www.linkedin.com/company/legend-capital). Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More